Liquidia (LQDA) Cash & Equivalents (2020 - 2026)
Liquidia's (LQDA) quarterly Cash & Equivalents came in at $222.8 million in Q1 2026, up 31.24% year-on-year from $169.8 million in Q1 2025, and up 16.84% quarter-over-quarter from $190.7 million in Q4 2025.
Liquidia (LQDA) Cash & Equivalents (2020 - 2026) Analysis & Trends
Liquidia's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $222.8 million for Q1 2026.
- On a quarterly basis, Cash & Equivalents rose 31.24% year-over-year to $222.8 million in Q1 2026; TTM through Mar 2026 was $222.8 million, a 31.24% increase from a year earlier, with the FY2025 full-year figure at $190.7 million, up 8.05% from the prior year.
- Cash & Equivalents grew to $222.8 million in Q1 2026 per LQDA's latest filing, from $190.7 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $222.8 million in Q1 2026 and bottomed at $57.8 million in Q1 2022.
- The 5-year median for Cash & Equivalents is $133.1 million (2024), against an average of $134.2 million.
- Across the five-year window, Cash & Equivalents surged 168.11% in 2024 and dropped 22.94% in 2025, its largest moves.
- Year by year, Cash & Equivalents stood at $93.3 million in 2022, then dropped by 10.3% to $83.7 million in 2023, then soared by 110.9% to $176.5 million in 2024, then advanced by 8.05% to $190.7 million in 2025, then gained by 16.84% to $222.8 million in 2026.
- Per Business Quant, the three latest LQDA Cash & Equivalents figures stand at $222.8 million (Q1 2026), $190.7 million (Q4 2025), and $157.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 222.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 222.79 Mn |
| Dec 31, 2025 | 190.68 Mn |
| Sep 30, 2025 | 157.50 Mn |
| Jun 30, 2025 | 173.42 Mn |
| Mar 31, 2025 | 169.76 Mn |
| Dec 31, 2024 | 176.48 Mn |
| Sep 30, 2024 | 204.37 Mn |
| Jun 30, 2024 | 133.09 Mn |
| Mar 31, 2024 | 157.86 Mn |
| Dec 31, 2023 | 83.68 Mn |
| Sep 30, 2023 | 76.23 Mn |
| Jun 30, 2023 | 88.20 Mn |
| Mar 31, 2023 | 94.41 Mn |
| Dec 31, 2022 | 93.28 Mn |
| Sep 30, 2022 | 98.32 Mn |
| Jun 30, 2022 | 103.84 Mn |
| Mar 31, 2022 | 57.80 Mn |
| Dec 31, 2021 | 57.49 Mn |
| Sep 30, 2021 | 64.10 Mn |
| Jun 30, 2021 | 67.89 Mn |